[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -3.00 -1.92% 153.00 155.00 157.00 156.00 156.00 156.00 47,727 16:35:16
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 49.2 -56.5 -72.8 - 274

Amryt Pharma Share Discussion Threads

Showing 4401 to 4416 of 6725 messages
Chat Pages: Latest  185  184  183  182  181  180  179  178  177  176  175  174  Older
DateSubjectAuthorDiscuss
28/2/2019
11:35
Best to do what I've done, Bermudashorts and put mdalos on filter. He's just a wind up merchant who posts just to get a response then like the COWARD he is deletes his posts so that his nasty nonsense can't be subjected to ridicule in the future. Unfortunately mdalos and Bronxville on the lse bb are cynical, nasty, individuals without any social conscience and assume everyone else has a similar mindset to them. Best to ignore them as they have no influence on the share price I still hold 5k of shares as it gives me an excuse to continue to follow AMYT and post on this bb. I will probably top up as we get closer to the 2018 final results expected in around 7 weeks time.
papillon
28/2/2019
09:59
I have mdalos on filter, but he no doubt posted something negative, richpassi and will soon delete his post if he hasn't done so already! LOL. mdalos is so, so, predictable! LOL. I presume the Irish Victor Meldrew, Bronxville, will post a similarly negative post on the lse bb. LOL. So, so, predictable!
papillon
28/2/2019
09:31
Thanks diamondstar1, despite my ignorance they were my thoughts too!
bazworth
28/2/2019
08:39
I see the news as immensely positive Mdalos. Inclusion of young children aged 21 days - 4 years will open up recruitment criteria. This will mean that they should have some data on this study population at study completion. Instead of having to run a separate paediatric development program - they can obtain data from the EASE study for all paediatric age groups. This has 2 major advantages: 1) Probably save up to £2 million on separate paediatric study 2) When applying for Marketing Authorization, can seek use of Episalvan for adult and all paediatric age groups at same time.
diamondstar1
28/2/2019
07:57
Yes previously minimum age for recruitment was 4 years but now it's 3 weeks which opens up a whole new group of patients from babies to 4 year olds. Should really speed up recruitment as existing trial centres will be able to revisit their patient populations and offer a place on the trial to their younger patients. Clearly a move that the DMC would never have sanctioned if there were any safety concerns. Good stuff.
bermudashorts
28/2/2019
07:10
Thank goodness!
bazworth
28/2/2019
07:06
Can now enrol children for phase 3 trial ....this has got to be a positive !
richpassi
23/2/2019
14:41
Bronxville, on the lse bb, is Ireland's answer to Victor Meldrew. He's Mr Negative. He never, ever, sees the positive side to anything. Whilst that's not a bad trait for a poster on these bb's considering the number of posters who look at the world of investing through rose tinted specs one can take negativity too far. It's the same with all the shares he invests in. Makes you wonder why he bothers investing in the first place.
papillon
22/2/2019
22:26
I only get annoyed, bazworth & chica, because Bronxville has been attempting to deramp AMYT on the lse bb for ages. He'll twist the facts, post spurious links and tell downright lies to suit his agenda. He started this current spat by criticising me on the lse bb. I tell the facts, whereas he twists the facts to suit his agenda. The German company was Birken AG, chica. It was reversed into FAST and the company then listed on AIM as AMYT. PS. I'm now down to my last 5,000 shares. I don't think it's worth me reading the ADVFN & lse bb's anymore. Just not worth it. This latest attempt at deramping AMYT by linking AP101 to liver toxicity is beneath contempt. In fact it's stupid as one can buy Imlan cream for psoriasis and other skin ailments over the counter and on the web in Germany. It's sold by AMYT in Germany. It's active ingredient is Betulin obtained from birch bark just like AP101. "Imlan Amryt has a range of dermo cosmetic products that we acquired with the Amryt AG transaction, which are sold under the Imlan brand. Completely free of emulsifiers, preservatives, colorants and fragrances and other additives or irritants, Imlan is marketed as a treatment for sensitive, allergy-prone and dry skin. It is also recommended for the basic care of eczema or psoriasis." hTTp://www.imlan.de/en/infothek/what-is-betulin.html PPS. If Bronxville wants to successfully deramp AMYT he needs to get a brain first. IMO liver toxicity wont be the reason AP101 fails to be successful it's whether it's more than marginally effective in treating EB. EDITED. 23/2/19. Botulin changed to Betulin. Typing error, or a Freudian slip? LOL. Now Botulin would be toxic as it's a very, very, lethal bacterial toxin!
papillon
22/2/2019
20:52
Aggressive posts, interesting observation and sadly very true. No need folks! Cheers Baz
bazworth
22/2/2019
20:04
Chica, Thanks very much for the response - am particularly interested as I didn't think there had been any previous UK clinical trials for AP101 (Oleogel-S10)in epidermolysis bullosa. When I was researching Amryt, the only previous EB trial that I had managed to find was a phase II which was carried out by Birken only in Germany (link below). Will try to find the UK trial that you mention as it would obviously be useful to see the results. Do you remember which hospital? Wow! you got samples from another patient on a clinical trial? It would be a shame if you stop posting and I hope you change your mind but if not then whether it's AP101 or not, I hope that an effective and safe treatment for EB will be just around the corner.
bermudashorts
22/2/2019
19:18
Hi,it was a NHS trial back in 2011-12ish. I think it was called Olegel.I forget the name of the company but it was German.We didn't participate in the trial directly but I knew someone involved so we got samples..It didn't work for us but it might have for others. I really don't want to get involved here anymore as some of the posts here are very aggressive.
chica1
21/2/2019
23:57
You could well be right Paps. If there's no takeover bids forthcoming and in the absence of any developments it could easily keep sliding as it runs out of cash. It really could go either way I think but ultimately it needs AP101 to come good to give it the boost it needs. Maybe it'll be a blessing in disguise and give us a re-entry opportunity later in the year!
greendragon777
21/2/2019
21:45
Hi Folks! Sorry for the radio silence over the last several weeks, I have been working on a deal recently and it's been super intense. I have also sold my entire position in AMYT and didn't want to say so here until I had closed my position entirely. It's with a heavy heart I had to liquidate but I simply needed to raise some funds for this opportunity that came up. I haven't really changed my mind on AMYT long term but I think we are all thinking the same thing that AMYT's short term funding requirements could come under serious pressure soon so this made my decision to close the position a little easier. I sold at a loss unfortunately but that's the risk involved so I made peace with that before I invested. I may still get back in in time for the trials but it's unlikely I will have any spare cash before the end of the year. I'll still be keeping an eye out and wish all remaining shareholder good fortune on their investment. This could be a takeover target at any point in my opinion and if they are running very low on cash might just be the best option for them. Interesting that Chica has first hand experience with EB. Would be interesting to get more input from her/him!
greendragon777
21/2/2019
20:09
Chica, Sorry, just to clarify, are you saying that you/a family member has previously taken part in an AP101 clinical trial for EB?
bermudashorts
21/2/2019
19:54
Was it an improvement on existing treatments, or no better, chica?
papillon
Chat Pages: Latest  185  184  183  182  181  180  179  178  177  176  175  174  Older
ADVFN Advertorial
Your Recent History
LSE
AMYT
Amryt Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210802 20:06:21